Key Takeaways Quest Diagnostics is projected to post 13.4% revenue growth and 9.4% EPS growth in Q2 2025. DGX may see gains from Advanced Diagnostics, new MRD blood tests and expanded payer access. DGX likely drove operating income growth through acquisitions and AI-powered efficiency programs.Quest Diagnostics (DGX) is set to release its second-quarter 2025 results on July 22, before the market opens.The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.21 in the last reported ...